Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant
Molecular Genetics & Genomic Medicine · 2026
DOI: 10.1002/mgg3.70304 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Genetics & Genomic Medicine, 2026. Verfasst von Özlem Yayıcı Köken und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, Akdeniz University Faculty of Medicine, Antalya, Turkey. Hauptthemen laut MEDLINE: KRIT1 Protein, Hemangioma, Cavernous, Central Nervous System, Frameshift Mutation. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Familial cerebral cavernous malformation (CCM) is an autosomal dominant vascular disorder with age‐dependent penetrance and marked intrafamilial variability. KRIT1 loss‐of‐function variants are the most common genetic cause, but pediatric genotype–phenotype correlations remain limited.
Methods
Clinical, radiological, histopathological, and molecular findings of a pediatric family with suspected familial CCM were reviewed. Brain and spinal MRI, calvarial histopathology, whole‐exome sequencing, segregation analysis, and targeted literature review were performed.
Results
The index patient was a 14‐year‐old boy presenting with focal seizure and a progressively enlarging right parietal calvarial mass. MRI revealed multiple cerebral and cerebellar CCMs with a cervical intramedullary cavernous malformation. The calvarial lesion was excised and confirmed as hemangioma. Whole‐exome sequencing identified a previously unreported heterozygous KRIT1 initiation‐region duplication, NM_004912.4: c.2dup, predicted to result in p.(Met1IlefsTer31) with loss of all major functional domains. The same variant was detected in the clinically asymptomatic sibling with MRI‐confirmed multiple CCMs, whereas the mother was negative. The father had died from intracerebral hemorrhage, but genetic testing was unavailable.
Conclusion
This report expands the KRIT1 mutational spectrum and illustrates the wide clinical range of familial CCM, from asymptomatic radiological disease to epilepsy and fatal hemorrhage within one family. These findings support early molecular diagnosis, cascade screening, and susceptibility‐sensitive MRI surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurology, Department of Pediatrics, Akdeniz University Faculty of Medicine, Antalya, Turkey.
- Division of Pediatric Neurology, Department of Pediatrics, Prof. Dr. Süleyman Yalçın City Hospital, İstanbul, Turkey.
- Department of Medical Genetics, Yıldırım Beyazıt University Faculty of Medicine, Ankara Bilkent City Hospital, Ankara, Turkey.
- Department of Radiology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
- Department of Neurosurgery, Akdeniz University Faculty of Medicine, Antalya, Turkey.
ORCID-Profile: Özlem Yayıcı Köken, Mehpare Sarı Yanartaş, Hande Aygün, Ahmet Cevdet Ceylan, Kamil Karaali, Mehmet Saim Kazan
Zitieren
APA
Yayıcı Köken, Ö., Yanartaş, M. S., Aygün, H., Ceylan, A. C., Karaali, K., & Kazan, M. S. (2026). Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70304
Vancouver
Yayıcı Köken Ö, Yanartaş MS, Aygün H, Ceylan AC, Karaali K, Kazan MS. Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant. Molecular Genetics & Genomic Medicine. 2026. doi:10.1002/mgg3.70304
BibTeX
@article{YaycKken2026,
author = {Yayıcı Köken, Özlem and Yanartaş, Mehpare Sarı and Aygün, Hande and Ceylan, Ahmet Cevdet and Karaali, Kamil and Kazan, Mehmet Saim},
title = {Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant},
journal = {Molecular Genetics & Genomic Medicine},
year = {2026},
doi = {10.1002/mgg3.70304}
}
EUVIMED